Prime Minister Justin Trudeau announced $175 million for a Vancouver biotech company, AbCellera Biologics Inc., which has identified antibodies that could be used to create treatments or a vaccine, in an May 3, 2020 story. (Photo by THE CANADIAN PRESS)

Prime Minister Justin Trudeau announced $175 million for a Vancouver biotech company, AbCellera Biologics Inc., which has identified antibodies that could be used to create treatments or a vaccine, in an May 3, 2020 story. (Photo by THE CANADIAN PRESS)

Vancouver biotech company discovering antibodies for COVID-19 treatment

Prime Minister Justin Trudeau announced $175 million federal funding for AbCellera

There may be another valuable shield in the fight against COVID-19, and the head of a Vancouver biotech firm says it could buy time as researchers race to develop a vaccine.

Carl Hansen, CEO of AbCellera Biologics Inc., said a drug built with antibodies could be used to protect vulnerable populations until a vaccine is more widely available.

The antibodies would give patients all the molecular material they need to fight the disease instead of depending on their bodies to develop their own as with a vaccine, giving them faster protection, he said.

“A prophylactic antibody could well be more effective than a vaccine,” he said.

On Sunday, Prime Minister Justin Trudeau announced $175 million federal funding for AbCellera to support its work in discovering those antibodies using a high-tech platform.

The funding also supports the company’s plans to build technology and manufacturing infrastructure for antibody therapies against future pandemic threats.

In partnership with pharmaceutical giant Eli Lilly, AbCellera is among a handful of companies on track for clinical trials this summer.

“There are many groups trying to rapidly develop vaccines for COVID-19 and vaccines are a very important part of the global response,” Hansen said.

“What we’re doing is different. What we’re doing is searching through an immune response that was generated from an actual infection and recovery in a patient and then finding that one antibody out of the literally millions that is best suited to stop the virus and that can be manufactured,” he said.

In 2012, Hansen said AbCellera recognized it could combine technologies from artificial intelligence, genomics, microfluidics and immunology to quickly search through natural immune systems to find antibodies that fight infection.

Two years ago, AbCellera began working with the Defense Advanced Research Projects Agency in the United States as part of a program to “radically accelerate” pandemic response, Hansen said. The company was working on simulations using its antibody-identifying technology when the COVID-19 pandemic struck.

“We quickly pivoted our efforts,” Hansen said.

Using blood samples from one of the first recovered COVID-19 patients in the United States on Feb. 25, AbCellera began screening millions of cells.

It narrowed down 500 unique human antibodies against the virus to a set of 24 that showed high promise of being therapeutic, he said.

“More recently we have further refined that set to a single antibody that is now being manufactured with the objective of having a first in-human trial start in July,” Hansen said.

What typically takes up to five years has been accelerated to less than four months, he said.

Vaccines and antibody-based prevention drugs work differently. With a vaccine, you inject a patient with a weakened virus or part of a virus to stimulate the immune system’s natural production of antibodies. With a prophylactic antibody, you insert the antibodies into the patient, Hansen said.

There are benefits and drawbacks. On one hand, prophylactics create more immediate protection because there’s no waiting period for the body to create its own antibodies. It’s also more broadly effective, because not all patients’ immune systems may be up to the task of producing their own antibodies.

On the other hand, a substantial number of antibodies must be administered to the patient in order to protect them.

“What that means is that the ability to manufacture hundreds of millions or even a billion doses of a vaccine is something well within the realm of possibility today. Making that many doses of antibodies is not,” he said.

That would mean giving the antibody to select groups of people at risk, such as health workers or the elderly, Hansen said.

The World Health Organization recommends that pharmacological treatment for COVID-19 should not be used outside of clinical trials.

On April 27, British Columbia’s COVID-19 therapeutics committee issued the same warning.

“There are no proven therapies for the prevention or treatment of COVID-19. All agents have the possibility of associated harm, and pharmaceutical supplies province-wide and nationally for many of the possible agents are severely limited,” it said.

For Hansen, research and development during the pandemic has not been business as usual.

“It’s not a race against our competitors nearly as much as it’s a race against the virus,” he said.

“What matters most is we get a therapy out there that works for patients and do so as quickly as possible.”

Amy Smart, The Canadian Press

Coronavirus

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Kelowna City Hall. (Michael Rodriguez - Capital News)
Kelowna’s 2021 preliminary budget proposes 4.27% tax increase

Proposed budget calls for eight new RCMP officers

Good Samaritan Mountainview Village located at 1540 KLO Road in Kelowna. (Good Samaritan Society)
First long-term care resident dies from COVID-19 in Interior Health

Man in his 80s dies following virus outbreak at Mountainview Village

(File)
One death and 82 new cases of COVID-19 in Interior Health

1,981 total cases, 609 are active and those individuals are on isolation

The former BC Tree Fruits office building at 1473 Water Street has been sold. (Contributed)
BC Tree Fruits downtown Kelowna office sold for $7.5M

Historic building sold for 44 per cent more than the $5.2-million asking price

Vernon-North Okanagan RCMP was called to a report of a fight at an Okanagan Landing Halloween party Saturday, Oct. 31, but issued the homeowner a ticket  under the COVID-19 Related Measures Act for having too many people at the party. (Black Press file photo)
West Kelowna man, dog rescued from carbon monoxide poisoning

The man was quickly transported to the hospital

Motorists wait to enter a Fraser Health COVID-19 testing facility, in Surrey, B.C., on Monday, Nov. 9, 2020. THE CANADIAN PRESS/Darryl Dyck
Another 694 diagnosed with COVID-19 in B.C. Thursday

Three more health care outbreaks, 12 deaths

Police responded to W.L. Seaton Secondary after reports of young man attempting to smash car windows in the student parking lot on Wednesday, Sept. 25, 2019. (Facebook)
Case of COVID-19 at North Okanagan high school

Member of W.L. Seaton Secondary exposure Nov. 26

The aftermath of the 3 a.m. fire in Keremeos. (Keremeos Fire Department)
Fire and explosion wakes Keremeos residents

A motorhome was consumed and a boat severely damaged after the 3 a.m. fire

A demonstrator wears representations of sea lice outside the Fisheries and Oceans Canada offices in downtown Vancouver Sept. 24, demanding more action on the Cohen Commission recommendations to protect wild Fraser River sockeye. (Quinn Bender photo)
First Nations renew call to revoke salmon farm licences

Leadership council implores use of precautionary principle in Discovery Islands

Ten-month-old Aidan Deschamps poses for a photo with his parents Amanda Sully and Adam Deschamps in this undated handout photo. Ten-month-old Aidan Deschamps was the first baby in Canada to be diagnosed with spinal muscular atrophy through Ontario’s newborn screening program. The test was added to the program six days before he was born. THE CANADIAN PRESS/HO, Children’s Hospital Eastern Ontario *MANDATORY CREDIT*
First newborn tested for spinal muscular atrophy in Canada hits new milestones

‘If Aidan had been born any earlier or anywhere else our story would be quite different’

Margaret Holm
HOLM: Better Bicycle Lanes

Margaret Holm writes about solutions to global warming

The newly opened Switzmalph Child Care Centre at Salmon Arm offers culturally enriched programs featuring the Secwépemc culture but is open to children of all heritages. (Martha Wickett - Salmon Arm Observer)
Video: Switzmalph Child Care Centre shares culture with Shuswap community

New daycare at Salmon Arm offers Secwépemc culturally enriched programs to children of all heritages

Cannabis bought in British Columbia (Ashley Wadhwani/Black Press Media)
Is it time to start thinking about greener ways to package cannabis?

Packaging suppliers are still figuring eco-friendly and affordable packaging options that fit the mandates of Cannabis Regulations

Man walking in the winter downtown.
Dyer: The role of air tightness testing in energy efficiency

Kristy Dyer has a background in art and physics and consulted for Silicon Valley

Most Read